Molecular Imaging and Biology

, Volume 12, Issue 6, pp 608–615 | Cite as

Radiochemical Synthesis, Rodent Biodistribution and Tumor Uptake, and Dosimetry Calculations of [11C] Methylated LY2181308

  • Carmen S. Dence
  • Richard Laforest
  • Xiankai Sun
  • Terry L. Sharp
  • Michael J. Welch
  • Robert H. Mach
Research Article
First Online:

Abstract

Purpose

The aim of the study was to develop a rapid and reproducible method to label LY2181308, an antisense oligonucleotide to Survivin, with carbon-11 in order to study its in vivo biodistribution and tumor uptake in rodents and its human dosimetry based on baboon data.

Methods

Randomly [11C] methylated LY2181308 was produced with [11C] methyl iodide. The biodistribution was performed in female Sprague–Dawley (SD) rats and EMT-6 tumor-bearing mice in the presence of nonradioactive LY2181308. Human dosimetry calculations were based on baboon PET studies.

Results

In SD rats, the kidney and liver were the organs with the most accumulation of radioactivity. Tumor uptake in mice was also relatively high after 5 min and remained constant for up to 1 h. Baboon dosimetry suggested that up to 42 mCi of radioactivity could be administered to human with a dose-limiting organ being the kidneys with a radiation dose of 32 µGy/MBq (0.118 rad/mCi).

Conclusions

[11C] Methylated LY2181308 to rodents and baboons showed its biodistribution, tumor uptake, and human dosimetry evaluation. These results should facilitate the understanding of the pharmacokinetics of LY2181308 prior to use as a potential new therapeutic agent in oncology as well as to warrant more in vivo validations as a potentially useful tumor-imaging agent.

Key words

Carbon-11 Oligonucleotides Dosimetry Tumor uptake PET 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We thank Nicole Fettig, Margaret Morris, Paul Eisenbeis, and Mark Nolte for their contributions to the animal studies and Bill Margenau and Dave Ficke for isotope production. We also thank Lynne Jones, Karen Dotson, and Joseph B. Dence for their editorial assistance. This work was supported by Eli Lilly and Co, Indianapolis, IN, USA.

References

  1. 1.
    Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921CrossRefPubMedGoogle Scholar
  2. 2.
    Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Rev Trends Mol Med 7:542–547CrossRefGoogle Scholar
  3. 3.
    Zaffaroni N, Daidone MG (2002) Survivin expression and resistance to anticancer treatments: perspective for new therapeutic interventions. Drug Resist Updat (review) 5:65–72CrossRefGoogle Scholar
  4. 4.
    Kallio MJ, Nieminen M, Eriksson JE (2001) Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J 15:2721–2723PubMedGoogle Scholar
  5. 5.
    Li F, Ambrosini G, Chu EY et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584CrossRefPubMedGoogle Scholar
  6. 6.
    Olie RA, Simoes-Wust P, Baumann B et al (2000) A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805–2809PubMedGoogle Scholar
  7. 7.
    Younes CK, Boisgard R and Tavitian B (2002) Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr Pharm Des 8:1451–1466CrossRefPubMedGoogle Scholar
  8. 8.
    Dolle F, Hinnen F, Vaufrey F et al (1997) A general method for labeling oligodeoxynucleotides with F-18 for in vivo PET imaging. J Labl Comp Radiopharm 39:319–330CrossRefGoogle Scholar
  9. 9.
    Tavitian B, Terrazzino S, Kuhnast B et al (1998) In vivo imaging of oligonucleotides with positron emission tomography. Nature Med 4:467–471CrossRefPubMedGoogle Scholar
  10. 10.
    Dence CS, Sun X, Mach RH, Welch MJ (2005) [11C]-methylated LY2181308, an antisense oligonucleotide to survivin: radiochemical synthesis and preliminary rodent biodistribution studies. J Labl Comp Radiopharm 48:S161Google Scholar
  11. 11.
    Dence CS, Laforest R, Sharp TL, Mach RH, Welch MJ (2007) [11C]-methylated LY2181308, an antisense oligonucleotide to survivin: part II-human dosimetry calculation. J Labl Comp Radiopharm 50:S449Google Scholar
  12. 12.
    Saleem A, Ranson M, Callies S, Lahn M, Prenant C, Brown G, Mathews JC, Dence CS, McMahon A, Price P (2009) Microdosing imaging pharmacokinetic (PK) study of the anti-sense oligonucleotide (ASO) to Survivin (LY 2181308) using positron emission tomography (PET): a novel paradigm in clinical drug development. J Clin Oncol 27(No 15S):3578Google Scholar
  13. 13.
    USP 32-NF 27 (2009) First supplement chapter <467>Google Scholar
  14. 14.
    Iskandar ZA and Al-Joudi FS (2006) Expression of survivin in fetal and adult normal tissue of rat. Malaysian J Pathol 28:101–106Google Scholar
  15. 15.
    Sohn DM, Kim SY, Baek MJ et al (2006) Expression of survivin and clinical correlation in patients with breast cancer. Biomed Pharmacotherapy 60:289–292CrossRefGoogle Scholar
  16. 16.
    Kennedy SM, O’Driscoll L, Purcell R et al (2003) Prognostic importance of survivin in breast cancer. Br J Cancer 88:1077–1083CrossRefPubMedGoogle Scholar
  17. 17.
    Tanaka K, Iwamoto S, Gon G et al (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127–134PubMedGoogle Scholar

Copyright information

© Academy of Molecular Imaging and Society for Molecular Imaging 2010

Authors and Affiliations

  • Carmen S. Dence
    • 1
  • Richard Laforest
    • 1
  • Xiankai Sun
    • 1
  • Terry L. Sharp
    • 1
  • Michael J. Welch
    • 1
  • Robert H. Mach
    • 1
  1. 1.Department of Radiology, Division of Radiological SciencesWashington University School of MedicineSaint LouisUSA

Personalised recommendations